Kibble & Prentice Expands Medical Liability Practice with Addition of Dyer
To address the increased difficulty health practitioners are reportedly having obtaining liability insurance, Kibble & Prentice has expanded its medical liability insurance practice.
Philip Dyer has joined Kibble & Prentice to head its growing medical liability practice. Dyer, who has been in the industry for 26 years, has 18 years of specialized experience in medical insurance liability, including management positions with The Doctors’ Company and Washington Casualty. He has also been a member of the Washington State Legislature and was a technical advisor to the Washington Health Care Commission.
Over the last five years Washington State has reportedly experienced a 33.4 percent increase in medical liability insurance rates, according to the Medical Liability Monitor, a publication of the U.S. Department of Health and Human Services.
Mike Gano, president of the Property Casualty division of Kibble & Prentice, noted, “The combination of our relationships with a wide number of carriers, our innovative approach to creating programs, and Phil’s deep expertise in medical liability issues, will enable us to identify and offer more carrier options to better meet the needs of doctors and clinics facing increasing liability challenges.”
Prior to being a vice president at The Doctors’ Company, Dyer, a Certified Insurance Counselor (CIC), was senior vice president at Washington Casualty Company, where he specialized in coverage liability for physicians and clinics.
- Report Calls out Most And Least Safe Cities for US Drivers
- State Farm Wins Dismissal of Homeowners’ Class Action Over Use of Xactimate Software
- Oracle Warns Health Customers of Patient Data Breach
- Trump’s Tariffs Threaten to Endanger the Cheap American Car
- Bayer Weighs Billions in Capital Raise for Lawsuits, Shares Tumble
- What Chief Claims Officers Can Do About a Growing Trend of Alleged Bad Faith Claims
- Alert for Contractors, Builders Insurers: Construction Defect Lawsuits Likely to Rise
- J&J Spars With Foes of $9 Billion Talc Cancer Plan as Trial Ends